CN102971307A - 作为kv7钾通道开放剂的哌啶基嘧啶酰胺 - Google Patents

作为kv7钾通道开放剂的哌啶基嘧啶酰胺 Download PDF

Info

Publication number
CN102971307A
CN102971307A CN2011800337518A CN201180033751A CN102971307A CN 102971307 A CN102971307 A CN 102971307A CN 2011800337518 A CN2011800337518 A CN 2011800337518A CN 201180033751 A CN201180033751 A CN 201180033751A CN 102971307 A CN102971307 A CN 102971307A
Authority
CN
China
Prior art keywords
disorder
depression
formula
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800337518A
Other languages
English (en)
Chinese (zh)
Inventor
M·M·克拉费伊
J·E·达沃伦
J·A·洛三世
R·J·马瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN102971307A publication Critical patent/CN102971307A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2011800337518A 2010-07-08 2011-06-20 作为kv7钾通道开放剂的哌啶基嘧啶酰胺 Pending CN102971307A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36250510P 2010-07-08 2010-07-08
US61/362,505 2010-07-08
PCT/IB2011/052686 WO2012004698A1 (en) 2010-07-08 2011-06-20 Piperidinyl pyrimidine amides as kv7 potassium channel openers

Publications (1)

Publication Number Publication Date
CN102971307A true CN102971307A (zh) 2013-03-13

Family

ID=44487037

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800337518A Pending CN102971307A (zh) 2010-07-08 2011-06-20 作为kv7钾通道开放剂的哌啶基嘧啶酰胺

Country Status (11)

Country Link
US (1) US8883812B2 (OSRAM)
EP (1) EP2590961A1 (OSRAM)
JP (1) JP5763758B2 (OSRAM)
KR (1) KR101449348B1 (OSRAM)
CN (1) CN102971307A (OSRAM)
AU (1) AU2011275393B2 (OSRAM)
CA (1) CA2804165C (OSRAM)
MX (1) MX2013000138A (OSRAM)
SG (1) SG186409A1 (OSRAM)
WO (1) WO2012004698A1 (OSRAM)
ZA (1) ZA201300499B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116589375A (zh) * 2018-02-20 2023-08-15 H.隆德贝克有限公司 作为Kv7钾通道开放剂的醇衍生物
CN119661413A (zh) * 2024-12-28 2025-03-21 齐鲁医药学院 Kv7钾离子通道开放剂及其制备方法和应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
ES2885424T3 (es) 2013-03-15 2021-12-13 Knopp Biosciences Llc Imidazo(4,5-B)piridin-2-il amidas como activadores del canal Kv7
ES2960991T3 (es) 2014-09-12 2024-03-07 Biohaven Therapeutics Ltd Benzoimidazol-1,2-ilamidas como activadores del canal Kv7
IL310136A (en) 2018-03-19 2024-03-01 Knopp Biosciences Llc KV7 channel activator preparations and methods of use
AR119521A1 (es) * 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
AU2020350614A1 (en) * 2019-09-17 2022-03-31 Biohaven Therapeutics Ltd. Methods of use for Kv7 channel activators
WO2021119018A1 (en) * 2019-12-09 2021-06-17 The Board Of Trustees Of The Leland Stanford Junior University A method to improve sleep quality in the elderly by controlling excitability of hypocretin neurons
WO2021211867A1 (en) * 2020-04-16 2021-10-21 Attune Neurosciences, Inc. Kv7 modulators for treating sleep or anxiety disorders
WO2022047311A1 (en) * 2020-08-28 2022-03-03 Pfizer Inc. Computerized decision support tool and medical device for respiratory condition monitoring and care
GB202306914D0 (en) * 2023-05-10 2023-06-21 Sania Rx Ltd Method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107259A (zh) * 2004-12-17 2008-01-16 塔克达剑桥有限公司 硅化合物及其用途
CN101258133A (zh) * 2005-09-09 2008-09-03 H.隆德贝克有限公司 嘧啶衍生物和它们作为kcnq钾通道开放剂的用途
US20080318979A1 (en) * 2007-06-13 2008-12-25 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
CN101563085A (zh) * 2006-08-23 2009-10-21 威朗国际制药公司 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361879A1 (en) * 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
US7322249B2 (en) 2005-07-07 2008-01-29 Delphi Technologies, Inc. Mounting for a probe sensor
US7683058B2 (en) * 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
US20090118285A1 (en) 2006-02-07 2009-05-07 H. Lundbeck A/S Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
EP2185149A1 (en) 2007-08-01 2010-05-19 H. Lundbeck A/S Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107259A (zh) * 2004-12-17 2008-01-16 塔克达剑桥有限公司 硅化合物及其用途
CN101258133A (zh) * 2005-09-09 2008-09-03 H.隆德贝克有限公司 嘧啶衍生物和它们作为kcnq钾通道开放剂的用途
CN101563085A (zh) * 2006-08-23 2009-10-21 威朗国际制药公司 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物
US20080318979A1 (en) * 2007-06-13 2008-12-25 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116589375A (zh) * 2018-02-20 2023-08-15 H.隆德贝克有限公司 作为Kv7钾通道开放剂的醇衍生物
CN119661413A (zh) * 2024-12-28 2025-03-21 齐鲁医药学院 Kv7钾离子通道开放剂及其制备方法和应用

Also Published As

Publication number Publication date
SG186409A1 (en) 2013-02-28
MX2013000138A (es) 2013-03-05
AU2011275393A1 (en) 2013-01-10
EP2590961A1 (en) 2013-05-15
JP5763758B2 (ja) 2015-08-12
JP2013531006A (ja) 2013-08-01
US8883812B2 (en) 2014-11-11
KR20130031323A (ko) 2013-03-28
CA2804165A1 (en) 2012-01-12
AU2011275393B2 (en) 2014-04-10
US20130150391A1 (en) 2013-06-13
CA2804165C (en) 2015-02-24
WO2012004698A1 (en) 2012-01-12
KR101449348B1 (ko) 2014-10-08
ZA201300499B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
US8883812B2 (en) Piperidinyl pyrimidine amides as Kv7 potassium channel openers
EP3423443B1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
EP4506001A2 (en) Substituted tetrahydrofurans as modulators of sodium channels
CN102933564B (zh) 用作β-分泌酶(BACE)抑制剂的5,6-二氢-2H-[1,4]噁嗪-3-基-胺衍生物
CN105814067B (zh) 作为钠通道调节剂的吡啶酮酰胺的前药
EP3150592B1 (en) Alk kinase inhibitor, and preparation method and use thereof
WO2024067744A1 (zh) 杂环取代喹唑啉及其制备方法和应用
CN112513020B (zh) 用于治疗疾病的kdm1a抑制剂
EP4253373A1 (en) Heteroaryl carboxamide compound
EP2964223A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP6278415B2 (ja) 置換４−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用
CN103717593A (zh) 调节激酶的组合物和方法
WO2019067503A1 (en) NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
CA3178647A1 (en) Substituted tricyclic amides, analogues thereof, and methods using same
TW202146381A (zh) 可用作RORγ調節劑的聯芳基類化合物
EP4587429A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
AU2024289347A1 (en) Nmt inhibitor, and preparation method therefor and use thereof
TW201726651A (zh) ２，３，４，５－四氫吡啶－６－胺衍生物
US20130184294A1 (en) Pyrimidones for Treatment of Potassium Channel Related Diseases
HK1177199A (en) Piperidinyl pyrimidine amides as kv7 potassium channel openers
HK40121637A (en) Substituted tetrahydrofurans as modulators of sodium channels
JP2026509368A (ja) Ｔｄｐ－４３及びタウ凝集の阻害剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1177199

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130313

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1177199

Country of ref document: HK